Please login to the form below

Not currently logged in
Email:
Password:

Five Prime Therapeutics

This page shows the latest Five Prime Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo combo misses the mark in pancreatic cancer

BMS’ Opdivo combo misses the mark in pancreatic cancer

Failed to reach primary endpoint of progression-free survial. A combination of Bristol-Myers Squibb’s Opdivo and Five Prime Therapeutics’ cabiralizumab failed to demonstrate efficacy in advanced pancreatic cancer. . ... in this randomised,

Latest news

  • BMS signs $1.74bn deal to boost immuno-oncology portfolio BMS signs $1.74bn deal to boost immuno-oncology portfolio

    Gainsaccess to Five Prime Therapeutics CSF1R antibody programme. Bristol-Myers Squibb has paid £350m upfront to Five Prime Therapeutics to gain rights to a development programme that complements its cancer immunotherapy ... BMS and Five Prime have been

  • BMS strikes $350m deal to boost its immuno-oncology pipeline BMS strikes $350m deal to boost its immuno-oncology pipeline

    Will collaborate with US biotech Five Prime Therapeutics. Bristol-Myers Squibb has signed a $350m deal to boost its immuno-oncology pipeline, following through on its promise last year to increase ... The pharma company will collaborate with San Francisco

  • GSK forms two new drug partnerships

    GSK has entered partnerships with both biotech Amplimmune to develop cancer therapies, and Five Prime Therapeutics for skeletal muscle disorders. ... GSK's deal with San Francisco-based Five Prime Therapeutics, which is worth around $139m before

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    cash and $30m equity) to gain access to CRISPR Therapeutics' technology for gene editing. ... Acquisition - company. 2, 300. Five Prime Therapeutics/ Bristol-Myers Squibb. CSF1R antibody programme, incl FPA008 (p1) in immunology/ oncology in combination

  • Pharma deals in May 2015 Pharma deals in May 2015

    Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Company divestment. 1, 530. Proteostasis Therapeutics / Astellas. Therapeutics modulating Unfolded Protein Response - multiple programmes. ... Cerdelga (eliglustat) sold by Vertex. Acquisition 75% royalty stream. 66. Five Prime Therapeutics / BMS.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved). ... 660. Five Prime Therapeutics/ BMS. Collaboration, licence. Drug discovery against two undisclosed targets in immune checkpoint

  • Pharma deals during March 2014 Pharma deals during March 2014

    The first of these deals was between recently floated Five Prime Therapeutics and Bristol-Myers Squibb (BMS) under which the companies will collaborate to discover, develop and commercialise immuno-oncology therapies. ... BMS is paying $20m upfront and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics